GlassScriptPhysician profile
Ozny Olvera
NPI 1356991244
$1,507.98
in general payments reported to CMS, 2019-2025
11 companies · $188 in 2025
The $188 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $298 · 2022: $172 · 2023: $445 · 2024: $405 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,006 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,005.59 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $703.36 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $431.95 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Jazz Pharmaceuticals INC. | $124.54 | 2021 | |
| Axsome Therapeutics, INC. | $102.34 | 2024-2025 | Sunosi |
| Insulet Corporation | $36.11 | 2024-2025 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.54 | 2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $19.96 | 2021 | |
| Corcept Therapeutics | $18.75 | 2023 | Korlym |
| Horizon Therapeutics Plc | $17.69 | 2021 | |
| Averitas Pharma INC. | $15.91 | 2025 | Qutenza |
| Idorsia Pharmaceuticals US INC | $14.83 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ozny Olvera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.